Intavis Peptide Services

Elevate your cancer immunotherapy innovations at the 𝐒𝐈𝐓𝐂 𝟐𝟎𝟐𝟒 annual meeting in 𝐇𝐨𝐮𝐬𝐭𝐨𝐧, 𝐍𝐨𝐯 𝟔-𝟏𝟎! Intavis Peptide Services is your trusted partner for 𝐚𝐥𝐥 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬, 𝐨𝐟𝐟𝐞𝐫𝐢𝐧𝐠 𝐞𝐧𝐝-𝐭𝐨-𝐞𝐧𝐝 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 from 𝐩𝐫𝐞-𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 to 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬. The Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston is the ideal gathering for innovators and industry leaders to connect, explore ground breaking advancements, and forge impactful collaborations in cancer immunotherapy. If peptides are central to advancing your immunotherapy research, connect with us to propel your work forward through our dedicated expertise. Don’t miss out—schedule your free consultation today by following the link in the comments! #SITC2024 #ClinicalTrials #CancerImmunotherapy

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 We’re interested in learning more about your peptide library needs to help us improve our offerings. Your feedback will allow us to better support your research and ensure we provide the right solutions. Please take a moment to share your preferences! #IntavisPoll #Peptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐑𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐃𝐞𝐬𝐢𝐠𝐧 𝐨𝐟 𝐚 𝐍𝐞𝐰 𝐒𝐡𝐨𝐫𝐭 𝐀𝐧𝐭𝐢𝐜𝐚𝐧𝐜𝐞𝐫 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐰𝐢𝐭𝐡 𝐆𝐨𝐨𝐝 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭" The authors present the rational design and synthesis of new short anticancer peptides (ACPs) with low toxicity and high antitumor efficacy. Based on the KLLK repeat motif, the researchers designed two optimal peptides, 14E and 14Aad, which demonstrated superior selectivity and anticancer activity in vitro and in vivo compared to the original KL-8 peptide. These peptides effectively disrupt cancer cell membranes and induce tumor cell death through multiple mechanisms, including apoptosis, membrane disruption, and reactive oxygen species (ROS) generation. Furthermore, the peptides showed low toxicity in normal cells and in animal models, making them promising candidates for future cancer therapy, especially in combination with the chemotherapy drug paclitaxel (PTX). The authors highlight the potential of using noncanonical amino acids and hydrophobic modifications to improve the efficacy and selectivity of anticancer peptides. Paper reference: Wu, X., Tian, Y., Ran, K., Yao, J., Wang, Y., Ouyang, X., ... & Ni, J. (2024). Rational design of a new short anticancer peptide with good potential for cancer treatment. European Journal of Medicinal Chemistry, 273, 116519. #Oncology #DrugDevelopment #Peptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭 𝐍𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧-𝐛𝐚𝐬𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬 represent a promising breakthrough in personalized medicine. This article delves into the potential of neoantigens to revolutionize cancer immunotherapy by targeting unique cancer cell mutations. It explores the key methods of identifying neoantigens, vaccine delivery platforms, and strategies for clinical application, highlighting the role of 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬. Intavis Peptide Services plays a pivotal role in supporting these developments with cutting-edge synthesis and analysis capabilities. Stay informed, Stay ahead with Intavis Peptide Services. October 2024: 𝐍𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐕𝐚𝐜𝐜𝐢𝐧𝐞; 𝐓𝐡𝐞 𝐊𝐞𝐲 𝐭𝐨 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬. #Neoantigens #CancerVaccines #PeptideTherapy #Immunotherapy

We look forward to meeting you in November 2024. 🔷 Meet Dr. Christian Stumpp, MBA, Ph.D., at the Society for Immunotherapy of Cancer (SITC) in 𝐇𝐨𝐮𝐬𝐭𝐨𝐧, 𝐔𝐒𝐀 November 6-10, 2024 🔷 Meet Dr. Christian Stumpp, MBA, Ph.D., and Dr. Oliver Reimann at TIDES: Oligonucleotides and Peptide Therapeutics EU in 𝐇𝐚𝐦𝐛𝐮𝐫𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 November 12-14, 2024 🔷 Meet Dr. Oliver Reimann at the Life Sciences Forum Saxony: Precision Medicine - From Diagnostics to Therapy in 𝐋𝐞𝐢𝐩𝐳𝐢𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 November 26, 2024 𝐏𝐥𝐞𝐚𝐬𝐞 𝐬𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐢𝐦𝐞 𝐬𝐥𝐨𝐭 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬. #SITC2024 #Oligonucleotides #Biotechnology #Peptides

We're excited to share that Dr. Oliver Reimann, our Head of Sales (non-GMP), will be attending TIDES: Oligonucleotides and Peptide Therapeutics Europe this November. Click the link below to connect with him directly! #Peptides #Tides2024

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐩𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐢𝐦𝐦𝐮𝐧𝐨𝐠𝐞𝐧𝐢𝐜𝐢𝐭𝐲: 𝐚 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐩𝐨𝐢𝐧𝐭 𝐨𝐟 𝐯𝐢𝐞𝐰" The authors explore the role of peptides in understanding and managing the immune response to therapeutic proteins, particularly focusing on the development of anti-drug antibodies (ADAs). Therapeutic proteins, such as monoclonal antibodies, can trigger immune reactions, causing treatment failure in some patients. Peptides, which are short chains of amino acids recognized by T and B cells, are crucial in these immune responses. The authors highlight how certain peptide regions are more immunogenic, influencing ADA formation, and discusses the use of peptide-based assays to detect ADAs more accurately than full protein assays. Additionally, it explores the potential of peptides to induce immune tolerance, particularly in conditions like hemophilia where immune tolerance to Factor VIII is critical. Overall, peptides offer valuable insights into the mechanisms of immunogenicity and hold promise for improving the safety and efficacy of therapeutic protein treatments. Paper reference: Real-Fernandez, F., Errante, F., Di Santo, A., Papini, A. M., & Rovero, P. (2023). Therapeutic proteins immunogenicity: a peptide point of view. Exploration of Drug Science, 1, 377-387. #Peptides #Therapeutic #Immunology

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 Excipients are vital in drug formulations, supporting the active ingredient in various ways. But do you know what they don’t do? 𝐒𝐡𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 – 𝐲𝐨𝐮𝐫 𝐢𝐧𝐩𝐮𝐭 𝐢𝐬 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞! #Intavis #Peptides #Excipients #DrugFormulations

Intavis Peptide Services is seeking a Werkstudent (M/W/D) in Technisches Büro. For more information, please contact me at hr@intavispeptides.com #career #job #humanresources #jobsearch #hiring #linkedin

Weltweit finden neoantigenbasierte Immunotherapien vermehrt Anwendung bei einer wachsenden Anzahl an verschiedenen Tumoren. Mit dieser zielgerichteten Therapie scheint es endlich möglich zu sein, den Tumor zu bekämpfen und das gesunde Gewebe zu schonen. Eine effektive Methode sind 𝐍𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧-𝐏𝐞𝐩𝐭𝐢𝐝-𝐕𝐚𝐤𝐳𝐢𝐧𝐞! Um diese zu produzieren, bedarf es tiefgehender Peptidexpertise und natürlich eine Passion für Qualität. Wir bei Intavis haben beides! Intavis Peptide Services ist der weltweit einzige one-stop-shop für neoantigen cancer vaccines: Peptide API & finales Injectable aus einer Hand. Hier geht’s zu unserer brandneuen, deutschen Website: https://rb.gy/bwkro0 #Intavis #NeoantigenPeptideVaccine #Peptides